Brief: Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
May 8 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* Oncolytics Biotech Inc announces FDA fast track
designation for Reolysin in metastatic breast cancer
* Oncolytics Biotech-based on co's understanding of
Reolysin, is pursuing metastatic breast cancer as its primary
focus for late-stage clinical testing
Source text for Eikon: ID:nPnbghvf3a
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer